The pan-solid tumor assay is designed to guide therapy selection and identify clinical trial options for patients with advanced stage solid tumors. It detects genomic alterations that are most relevant to diagnosis, therapy selection, prognosis, and clinical trial options in solid tumors.
The addition of IHC and ancillary testing provides comprehensive information for therapy selection beyond standard CGP testing. It is ideal for patients with newly diagnosed, recurrent, or progressive advanced cancer with an unusual clinical presentation who need thorough coverage for clinical investigation.
Diagnosis information you provide will determine tumor type-directed IHC and ancillary testing. See PanTracer Pro Testing by Cancer Type for the full list of associated add-ons by cancer diagnosis.